Home Cart Sign in  
Chemical Structure| 13434-13-4 Chemical Structure| 13434-13-4

Structure of Actinonin
CAS No.: 13434-13-4

Chemical Structure| 13434-13-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Actinonin is a bioactive peptide and antibiotic that is a potent inhibitor of CD13 and aminopeptidase (leucine aminopeptidase).

Synonyms: Ro 06-1467; (-)-Actinonin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Actinonin

CAS No. :13434-13-4
Formula : C19H35N3O5
M.W : 385.50
SMILES Code : O=C(N[C@@H](C(C)C)C(N1[C@H](CO)CCC1)=O)[C@H](CCCCC)CC(NO)=O
Synonyms :
Ro 06-1467; (-)-Actinonin
MDL No. :MFCD00080257

Safety of Actinonin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HT22 cells 2μM 24 h To evaluate the protective effects of Actinonin against mutant Tau-induced mitochondrial and synaptic toxicities. Results showed that Actinonin treatment increased the expression of mitochondrial fusion genes, decreased the expression of mitochondrial fission genes, and improved mitochondrial respiration and cell survival. Pharmacol Res. 2021 Dec;174:105973
P493 cells 26 μM Actinonin selectively kills c-Myc-overexpressing P493 cells regardless of proliferation status Cell Death Dis. 2014 Mar 27;5(3):e1152
HeLa cells 150 μM 6 h Actinonin treatment led to YFP-Parkin accumulation on mitochondria, but Parkin recruitment was not observed in PINK1 KO cells. J Cell Biol. 2017 Oct 2;216(10):3231-3247
HeLa cells 150 μM 4 h Actinonin treatment caused YFP-Parkin to accumulate in focal spots on polarized mitochondrial subdomains. J Cell Biol. 2017 Oct 2;216(10):3231-3247
NCI-A549 cells 250 μM 48 h To study the uptake of Actinonin nanoformulation in NCI-A549 cells, results showed apoptotic features such as cellular blebbing, loss of mitochondrial integrity, numerous vacuoles and shrunken nucleus. Drug Deliv. 2022 Dec;29(1):2403-2413
SH-SY5Y cells 5, 10, 20, 30, 50, 100 µg/ml 3 h To evaluate the potency of HIF PHD inhibitors and compare the IC50 values of different inhibitors. Results showed that oxyquinoline-type inhibitors were more effective than roxadustat and vadadustat in the HIF ODD-luc reporter assay. J Clin Invest. 2004 Oct;114(8):1107-16
Arabidopsis thaliana cells 100 μM Study the effect of actinonin on chloroplast development, showing induction of an albino phenotype. EMBO J. 2003 Jan 2;22(1):13-23
K562 cells 26 μM 5 days Investigate the inhibitory effect of Actinonin on K562 cell proliferation, results showed Actinonin inhibits cell proliferation through intracellular interactions Cancer Lett. 2002 Aug 28;182(2):113-9.
U937 cells 13 μM 5 days Investigate the inhibitory effect of Actinonin on U937 cell proliferation, results showed Actinonin inhibits cell proliferation through intracellular interactions Cancer Lett. 2002 Aug 28;182(2):113-9.
RBL-2H3 mast cells 100 µM 1 h Inhibition of Mep1A activity, significantly reducing TNF-α mRNA and protein levels in IgE-treated mast cells Br J Pharmacol. 2020 Jun;177(12):2872-2885

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CLP model Intraperitoneal injection 400 μg 0 and 6 hours post-surgery Actinonin reduced renal injury in the CLP mouse model Kidney Int. 2006 Aug;70(3):496-506
BALB/c mice Lung adenocarcinoma model Intraperitoneal injection 150 mg/kg Free Actinonin five times per week, nanoformulation two times per week, for one week To evaluate the therapeutic efficacy of free and nanoformulated Actinonin in lung adenocarcinoma model, results showed comparable efficacy of nanoformulation to free drug in terms of reduced tumor burden, 100% survival and downregulation of EGFR, FOLR1 and PDF expression. Drug Deliv. 2022 Dec;29(1):2403-2413

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.59mL

0.52mL

0.26mL

12.97mL

2.59mL

1.30mL

25.94mL

5.19mL

2.59mL

References

 

Historical Records

Categories